(Q38128366)

29 August 2017

title

Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban (English)

1 reference

29 August 2017

1 reference

1 reference

1 reference

Trevor Baglin

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

12 August 2013

1 reference

British Journal of Haematology

29 August 2017

published in

1 reference

29 August 2017

volume

163

1 reference

29 August 2017

issue

2

1 reference

29 August 2017

page(s)

160-167

1 reference

Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology

29 August 2017

cites work

1 reference

Potential inaccuracy of point-of-care INR in dabigatran-treated patients.

21 January 2018

1 reference

Oral rivaroxaban for symptomatic venous thromboembolism

21 January 2018

1 reference

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

21 January 2018

1 reference

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

21 January 2018

1 reference

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

21 January 2018

1 reference

Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

21 January 2018

1 reference

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons

21 January 2018

1 reference

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.

21 January 2018

1 reference

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

21 January 2018

1 reference

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

21 January 2018

1 reference

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

21 January 2018

1 reference

A specific antidote for dabigatran: functional and structural characterization

21 January 2018

1 reference

How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch

21 January 2018

1 reference

Dabigatran versus warfarin in the treatment of acute venous thromboembolism

21 January 2018

1 reference

Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran

21 January 2018

1 reference

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

21 January 2018

1 reference

Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran

21 January 2018

1 reference

Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests

21 January 2018

1 reference

Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12502

1 reference

29 August 2017

1 reference